Age-adjusted antitumoral therapy based on the demonstration of increased apoptosis as a mechanism underlying the reduced malignancy of tumors in the aged  by Itzhaki, Orit et al.
www.bba-direct.com
Biochimica et Biophysica Acta 1688 (2004) 145–159Age-adjusted antitumoral therapy based on the demonstration
of increased apoptosis as a mechanism underlying the reduced
malignancy of tumors in the aged
Orit Itzhaki1, Tatiana Kaptzan1, Ehud Skutelsky, Judith Sinai, Moshe Michowitz,
Annette Siegal, Ginnette Schibi, Monica Huszar, Lya Ben-Dor, Judith Leibovici*
Department of Pathology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 69978, IsraelReceived 16 May 2003; received in revised form 25 November 2003; accepted 25 November 2003Abstract
In view of the constant increase in the aged population, age-adjusted cancer therapy becomes an urgent target. Although cancer incidence
rises with age, paradoxically, growth rate and metastasis often proceed at a slower rate in the aged. Determining the mechanism(s) underlying
this reduced tumor progression in the old might have implications for a rational design of age-adjusted therapy. Thus far, decreased cell
proliferation or immune response modifications were suggested as possible mechanisms. We show here that an increased tendency to
apoptotic tumor cell death in the aged could constitute an additional mechanism. Based on this mechanism, we compared the therapeutic
efficacy of two apoptosis inducers, hydrocortisone and adriamycin, on AKR lymphoma and B16 melanoma growth in young and old mice.
Treatment with hydrocortisone acetate inhibited tumor growth practically only in old mice in the two tumor systems. Similar effects were
obtained with adriamycin treatment of AKR lymphoma but opposite results were seen with B16 melanoma. We thus demonstrated, in three of
the four tumor-therapeutic modality systems examined, an age-related antitumoral efficacy of two apoptosis-inducing agents, with tendency
for a remarkably more pronounced effect in aged mice.
D 2004 Elsevier B.V. All rights reserved.Keywords: Cancer treatment; Aging; Apoptosis induction; Tumor progression; Age-dependent therapy design
1. Introduction humans [1] and in experimental models. [2] For example,The research on tumor development and its treatment in
the elderly should gain an importance in view of the
constant rise of the fraction of aged individuals in the
population of Western countries. Despite the steady increase
of the aged population, which bears most of the cancer
burden, only few studies have been devoted to the effect of
age on tumor progression and on age-adjusted cancer
therapy. Most experimental studies on cancer are (inappro-
priately) performed on young animals. Such studies may be
irrelevant to the aged organism.
Cancer incidence is known to augment with age. Para-
doxically, however, tumor growth and metastasis were often
found to proceed at a slower rate in aged organisms, in both0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2003.11.009
* Corresponding author. Tel.: +972-3-6409630; fax: +972-3-6409141.
E-mail address: jleibov@post.tau.ac.il (J. Leibovici).
1 These authors contributed equally to this study.bronchogenic cancer [3] and cancers of breast [4] and colon
[5] were reported to grow slower and metastasize less in old
patients. With regard to experimental tumors, growth has
often been shown to be slower and to display a reduced
aggressiveness in aged as compared to young animals
[2,6,7]. We have also reported this phenomenon in the
B16 melanoma [8,9] and in the AKR lymphoma [10].
The mechanisms responsible for the reduced tumor
progression in the aged compared to young organisms have
not yet been established. Decreased proliferative capacity in
the old has been suggested [11] as well as a decline in the
availability of growth factors with age [12]. Modifications
in anti-tumoral immune reactions with host age have been
demonstrated by Kaesberg and Ershler [13] and by our-
selves [9]. We have recently suggested that an increased
apoptotic cell death could be responsible for the reduced
malignant behavior of tumors in the aged [10].
Understanding the mechanism of the differential biolog-
ical behavior of tumors in relation to host age is of
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eventual exploitation of these mechanisms for a rational
design of cancer therapy appropriate for the aged organism.
The age-related differential biological behavior of tumors
actually implies the necessity of a differential therapy for
cancer patients of different ages. Very few experiments of
this type have been performed [14–16].
In the present study, we demonstrate that the rate of
apoptotic cell death in two tumors, B16 melanoma and AKR
lymphoma, was higher in old mice than in those growing in
young mice. We further examined the possibility, which
seemed logical in view of the above, that apoptosis-inducing
therapy could be more efficient against tumors in aged
organisms than against those in young ones. As far as we
are aware, this is the first study with such an approach
(according to a search in Medline using as keywords:
apoptosis, aging, cancer and therapy, 69 references were
found but none was really relevant).
While for decades, the major goal of cancer treatment by
cytotoxic agents was to inhibit proliferation of tumor cells, it
now appears that the primary mechanism by which most (if
not all) chemotherapeutic agents induce cell death is apo-
ptosis [17]. It was, in fact, found that cytotoxic drugs with
widely different modes of action and differing cellular
targets (antimetabolites, alkylating agents, topoisomerase
inhibitors or hormone antagonists) could induce apoptosis
in susceptible cells [18]. Indeed, susceptibility or resistance
to apoptosis of the tumor cells often determines the response
to chemotherapy of particular cancers [18].
Although a large number of publications supporting this
thesis are found in literature (4856 references according to
Medline using the keywords: chemotherapy, apoptosis and
cancer), curiously, in currently used screening assays, po-
tential anti-cancer drugs are selected on the basis of growth
inhibiting properties rather than on their ability to induce
apoptosis [19].
To compare the efficacy of apoptosis-inducing antitu-
moral therapy in young and old mice, we used in the
present study as apoptosis-inducing agents, hydrocortisone
(HC) and adriamycin (ADR). We examined the possibility
of an age-related differential efficacy of these treatments in
two tumor systems, the B16 melanoma and the AKR
lymphoma.
Adriamycin (doxorubicin) has been used for more than
30 years in treating a variety of malignancies [20]. Never-
theless, the mechanism of ADR has been a subject of
controversy. A number of mechanisms have been suggested,
such as intercalation into DNA, damage to DNA via free
radical formation, interference with DNA unwinding or
DNA strand separation by helicase, inhibition of topoiso-
merase II as well as effects on the cell membrane [21].
Elmore et al. [21] recently demonstrated that ADR treatment
of breast tumor cells induced replicative senescence which
involved telomere dysfunction. Anthracyclines were further
shown to induce apoptotic cell death [22–24]. This could
possibly represent a cell response resulting from previouscellular events. Evidence proving that ADR induces apo-
ptosis includes induction of DNA fragmentation and cell
shrinkage [23,24]. Moreover, ADR-resistant multiple mye-
loma cell lines displayed various alterations in expression of
genes involved in apoptosis-signaling pathways [25].
Glucocorticoids (GC) are used as immunosuppressive
and anti-inflammatory agents in managing disorders of
heightened immunity [26] as well as against lymphoproli-
ferative diseases, mainly hematological cancers [27]. About
20 years ago, it was recognized that GC-induced cell death
exhibits morphologic features characteristic of apoptosis
[28]. Additional studies demonstrated that glucocorticoids
are potent apoptosis-inducing agents, at pharmacological
[28] and physiological levels [29].
Based on our experiments demonstrating a mechanism of
the differential biological behavior of tumors in old as
compared to young mice (modified apoptotic cell death),
we show a differential age-related response to apoptosis-
inducing therapy.2. Materials and methods
2.1. Mice and tumors
Studies on animal models were performed according to
the guidelines of Tel-Aviv University. C57BL/6J and AKR/
J mice were purchased from the Tel-Aviv University Breed-
ing Center. Two age groups were used: young mice, 6–
8 weeks for both C57BL/6J and AKR/J mice; old mice,
16–24 months for C57BL/6J mice and 7–9 months for
AKR/J mice. We chose this age as ‘‘old’’ for the AKR mice,
because the life-span of this strain of mice is short, and in
order to avoid the use of mice with spontaneous tumors
which begin to appear at around 6 months. Mice were
examined (by palpation of inguinal lymph nodes) for
presence of spontaneous tumors, and those which devel-
oped such tumors were not included in the experiments.
Tumor cell suspensions of both AKR lymphoma and B16
melanoma were prepared as previously described [30]. For
experiments comparing the biological behavior of tumors
and the various tests for apoptosis, the procedures were as
follows: tumor cells (2 105 in 0.2-ml RPMI-1640 medi-
um; Sigma-Aldrich, Rehovot, Israel) were inoculated sub-
cutaneously (s.c.) in the back of mice. Tumor growth was
evaluated by recording the incidence and by measuring two
to three times a week the diameter of the tumors formed at
the s.c. site of inoculation. Mice mortality was recorded
daily.
For the tests related to apoptosis, tumors were taken from
mice when they reached diameters of 15–20 mm in the
young, which occurred around day 20 after tumor inocula-
tion in the case of B16 melanoma and around day 12 in the
case of AKR lymphoma. The size of the tumors was chosen
so that necrosis could be avoided as far as possible but so
that they could be large enough (in old mice as well) to
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could slightly differ from experiment to experiment but
tumor sizes were comparable among experiments.
Treatment of tumor-inoculated mice with apoptosis-in-
ducing agents was performed as follows: AKR/J mice were
inoculated s.c. with 1104 cells of AKR lymphoma and
C57BL/6J mice were inoculated s.c. with 2.2 105 cells of
the B16 melanoma. This inoculum was chosen since we
recently demonstrated that at this particular inoculum, the
melanoma displayed maximal differential biological behav-
ior between young and old mice (unpublished results).
Treatment was performed with single doses of 500 or 25
Ag per mouse of HC or ADR, respectively, 24 h following
tumor inoculation. Each experimental group consisted of
five mice and each experiment was repeated four to seven
times.
2.2. DNA flow cytometry
Cells derived from primary tumor growths of AKR
lymphoma and B16 melanoma, grown in young or old
mice, were incubated with propidium iodide (50 Ag/ml)
(Sigma-Aldrich) following the procedure of Vindelov [31].
The data were analyzed on a Cell Quest Software BP,
MultiCycle Phoenix Flow Systems (Phoenix, Arizona).Fig. 1. Differential biological behavior of B16 melanoma and AKR lymphoma in
lymphoma in young (o) and aged (.) mice in representative experiments. Inse
( P< 0.0125 and P< 0.025, respectively) and for AKR lymphoma on days 13 an
young (o) and old (.) mice inoculated with B16 melanoma. (C) Average survi
survival of young and old mice bearing B16 melanoma.2.3. ApopTag staining
Apoptosis was identified by labeling the DNA 3V-OH
nick-ends using a variant of TUNEL staining. ApopTag
staining was carried out according to the manufacturer’s
instructions using the materials provided in the kit (Apop-
Tag, Intergen Company, New York). After deparaffinization
in xylene and rehydration in a series of decreasing concen-
trations of alcohol, the 5-Am-thick tissue sections were
incubated at 37 jC for 1 h in the presence of terminal
deoxynucleotidyl transferase (TdT) and digoxigenin-labeled
nucleotides. After washing, anti-digoxigenin-peroxidase
was added to the slides which were incubated in a humid-
ified chamber for 30 min at room temperature. After
washing in PBS, the slides were stained with diaminoben-
zidine (Sigma-Aldrich) and then counterstained with 1%
methylgreen (Vector, Burlingame, California). The percent-
age of apoptotic bodies was determined at high power
fields. A total of 300 cells was counted.
2.4. DNA fragmentation analysis by agarose gel
electrophoresis
The purification of genomic DNA was done with Pure-
gene DNA Isolation Kit (Gentra, Minneapolis, Minnesota).
sica Acta 1688 (2004) 145–159 147young and old mice. (A) Average tumor size of B16 melanoma and AKR
rts: Average diameters of tumors for B16 melanoma on days 22 and 29
d 17 ( P < 0.001 and P < 0.0005, respectively). (B) Kinetics of mortality of
val time of young and aged B16 melanoma-bearing mice. (D) Long term
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young or old mice, was analyzed by horizontal electropho-
resis during 2 h on 2% agarose gel (Talron, Rehovot, Israel)
and visualized by UV fluorescence after staining with
ethidium bromide (0.5 Ag/ml) (GibcoBRL, Rockville,
MA). As DNA marker, pUC18 DNA marker HaeIII digest,
102–587 b.p. (Sigma-Aldrich), was used in this study.
2.5. Analysis of Bcl-2 protein expression by flow cytometry
Single cell suspensions were washed with PBS and red
blood cells were removed by RBC buffer (Epicentre,
Addisson, WI). Cells were suspended at a concentration
of 2 107 cells/ml in saponine buffer (SB) (0.03% sap-
onine in 1% bovine serum albumin (BSA) in PBS, pH 7.4)
(Sigma-Aldrich) in order to permeabilize the cells [32]. The
cells were incubated with hamster anti-mouse-Bcl-2 mAbFig. 2. Effect of host age on apoptosis in B16 melanoma and AKR lymphoma:
pictures of ApopTag staining sections of B16 melanoma ( 400) and AKR lymph
of Apoptag+ cell content in tumors from young and old mice.(clone 3F11) (PharMingen, San Diego, CA), 1:250 for 30
min at 4 jC. After washing with SB, cells were incubated
with FITC-conjugated goat anti-Armenian hamster IgG
(Jackson ImmunoResearch Laboratories, West Grove, PA),
1:50 for 30 min at 4 jC. After two additional washings,
samples were analyzed on a FACSort Becton Dickinson,
San Jose, CA, with WinMDI 2.8 Joseph Trotter Scripps
data processing.
2.6. Analysis of Fas protein expression by flow cytometry
Cells prepared as for Bcl-2 analysis were washed in cold
buffer (1% FCS in PBS) and were suspended to a concen-
tration of 2 107 cells/ml. In order to reduce Fcgii/iii R-
mediated antibody binding, the cells were incubated with
0.25-mg Fc Block (clone 2.4G2) (PharMingen) per 106 cells
for 3 min at 4 jC. After washing, the cells were incubatedevidence at the cellular level. (A) Apoptotic cell content in representative
oma ( 200) in mice of different ages. (B and C) Quantitative comparison
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gen), 1:50 for 30 min at 4 jC in the dark. After washing
with cold buffer, cells were incubated with the same
secondary antibody as for Bcl-2 and analyzed by FACS.
2.7. Western blot analysis for caspases 8, 3 and 9
Total cell protein lysates were prepared as follows: cells
were lysed in 1% Nonidet P-40 lysis buffer (1% Nonidet P-
40, 150 mM NaCl, 50 mM Tris–HCl (pH 8.0) and 1 mMFig. 3. Profile of DNA flow cytometry in B16 melanoma and AKR lymphoma
experiments with B16 melanoma and AKR lymphoma, respectively. QuantitativeSodium vanadate) (Sigma-Aldrich) supplemented with pro-
tease inhibitor mixture (0.1 mM PMSF and 2 Ag/ml of
leupeptin and apoprotein) (Sigma-Aldrich) for 15 min on
ice. Lysates were centrifuged at 10,000 rpm for 5 min at 4
jC. Forty micrograms of total proteins was dissolved by
14% sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) and transferred to a nitrocellulose mem-
brane. The membranes were blocked for 2 h at room
temperature with 5% BSA. Primary antibodies reactive to
caspase-8 (1:1000), caspase-3 (1:2500) and caspase-9growing in young as compared to old mice. A and E show representative
evaluations of the data of four experiments with regard to cell proliferative
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(StressGen Biotechnologies Corp, Victoria, British Colum-
bia, Canada) were used for identification, incubating for 1
h with each of the antibodies. Five washes in TTBS (10 mM
Tris–HCl, 0.15 M NaCl, 0.1% Tween, pH 7.4) followed
each incubation. The caspases were detected by enhanced
chemiluminescence (ECL) using the substrate of Pierce
(SuperSignal West Pico Trial Kit; Pierce, Rockford, IL).
HeLa cell lysates (2 Ag/lane) (StressGen Biotechnologies)
served as positive control for caspases 8, 3 and 9. A
quantitative analysis was performed using the KODAK
1D 3.5 software.
2.8. Statistical evaluation
Statistical evaluation was performed for most data by
Student’s t test. The Log-rank test [33] was used for the
cumulative incidence and mortality summarized from all
experiments. The v2 test was used to test the significance of
the differences between the treated and nontreated groups of
mice in long-term survivors.Fig. 4. Effect of host age on apoptosis of tumors: evidence at the molecular level. C
lymphoma from young and old mice. Upper part: representative experiments. E
antibody-positive cells. Lower part: quantitative evaluation of six experiments wi3. Results
3.1. Differential biological behavior of B16 melanoma and
AKR lymphoma in young and old mice
The biological behavior of the B16 melanoma and the
AKR lymphoma in young and old mice is presented in Fig.
1. A reduced tumor growth rate was observed in aged as
compared to young animals in both tumors (Fig. 1A and B).
As seen in the inserts, the differences between tumor size in
young and old mice were statistically significant in both the
B16 melanoma (P < 0.0125 on day 22) and the AKR
lymphoma (P < 0.001 on day 13). Mortality was markedly
inhibited in old as compared to young B16 melanoma-
bearing animals (Fig. 1B). The difference between young
and old mice, according to the average survival time (Fig.
1C), was statistically highly significant (P < 0.0025). More-
over, a significant number of long-term survivors (LTS)
were observed in both young and old mice, but the number
of LTS was higher in old than in young mice (Fig. 1D),
again statistically highly significant. The number of long-omparison of Bcl-2 and Fas protein expression in B16 melanoma and AKR
mpty areas: secondary antibody only; gray areas: anti-Bcl-2 or anti-Fas
th regard to Bcl-2+ and Fas+ cell populations.
O. Itzhaki et al. / Biochimica et Biophyterm survivors was 3/44 (6.8%) and 15/44 (34%) in young
and old mice, respectively. Thus, in old mice a fivefold
increase was found in long-term survivors as compared to
young animals. In AKR lymphoma, the differential age-
related reduced tumor growth was demonstrated by both
cumulative tumor incidence (not shown) and tumor size
(Fig. 1A). This was not seen, however, with regard to mice
mortality (see Figs. 6 and 7).Fig. 5. (A) Western blot analysis of caspases 8, 3 and 9 in B16 melanoma and AKR
active caspase. H—HeLa cell lysate. (B) Quantitative evaluation of four different
Comparison of DNA fragmentation in AKR lymphoma cells derived from young a
young; O—old.3.2. Evidence indicating that increased apoptosis consti-
tutes a mechanism of the age-related reduced tumor growth
rate in aged mice
Figs. 2–5 adduce evidence that tumors from old mice
have a higher propensity for undergoing apoptosis than
tumors in young animals. Staining of tumor cells by Apop-
Tag showed a higher content in apoptotic bodies in tumor
sica Acta 1688 (2004) 145–159 151lymphoma derived from young (Y) and old (O) mice. P—precaspase; A—
experiments. Empty columns—young mice; black columns—old mice. (C)
nd old mice. Lane ‘‘M’’ represents the DNA marker of different sizes. Y—
Fig. 6. Differential effect of hydrocortisone treatment on B16 melanoma and AKR lymphoma in young and old mice. Nontreated young (o) and old (.) tumor-
bearing mice; hydrocortisone-treated young (4) and old (E) tumor-bearing mice. A comparison of the average diameter of tumors on day 24 (for B16
melanoma) and on day 14 (for AKR lymphoma) is shown in the inserts. Inserts: Clear area—young nontreated; gray area—young treated; striated—old
nontreated; striated bold—old treated. The number of mice in each group was 5.
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ones, both in B16 melanoma and in AKR lymphoma (Fig. 2).
The increase in the average apoptotic cell content in old asFig. 7. Differential effect of adriamycin treatment on B16 melanoma and AKR ly
ADR-treated young (4) and old (E) mice. Inserts show the average diameter of tu
area—young nontreated; gray area—young treated; striated—old nontreated; striacompared to young mice was 18-fold in B16 melanoma and
about 11-fold in the case of AKR lymphoma, as was
calculated from Fig. 2B and C, respectively.mphoma in young and old mice. Nontreated young (o) and old (.) mice;
mors on day 28 for B16 melanoma and on day 14 for AKR lymphoma. Clear
ted bold—old treated. The number of mice in each group was 5.
Fig. 8. Effect of hydrocortisone treatment on the B16 melanoma and AKR lymphoma in young and old mice—cumulative incidence and mortality of all
experiments. Nontreated young (o) and old (.) tumor-bearing mice; treated young (4) and old (E) tumor-bearing mice. The inserts show the day of 50%
incidence and the mean survival time in young nontreated mice (clear area), in young treated (gray area), in old nontreated (striated area) and in old treated mice
(striated bold). The number of mice in each group is that appearing as total number of mice in Table 1.
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noma and AKR lymphoma derived from young and old
animals is presented in Fig. 3. Fig. 3A and E shows
representative experiments of B16 melanoma and AKRFig. 9. Effect of adriamycin treatment on the B16 melanoma and AKR lymph
experiments. Details as in Fig. 8.lymphoma, respectively. The figure further summarizes
the quantitative evaluation of several experiments done
with B16 melanoma (Fig. 3B–D) and AKR lymphoma
(Figs. 3F–H).oma in young and old mice—cumulative incidence and mortality of all
Table 1
Age-dependent effect of hydrocortisone and adriamycin treatment on B16
melanoma and AKR lymphoma: effect on long-term survivors
B16 melanoma AKR lymphoma
Age Treatment S/T %S Age Treatment S/T %S
Hydrocortisone treatment
Young Control 0/24 00.0 Young Control 0/20 0.0
Young HC 0/25 00.0 Young HC 0/20 0.0
Old Control 3/25 12.0 Old Control 0/18 0.0
Old HC 5/24 20.8 Old HC 1/18 5.6
Adriamycin treatment
Young Control 0/37 00.0 Young Control 0/25 0
Young ADR 16/35 45.7 Young ADR 5/25 20
Old Control 7/37 18.9 Old Control 0/25 0
Old ADR 7/35 20.0 Old ADR 11/25 44
Two age groups of mice were used: young mice, 6–8 weeks for both
C57BL/6J and AKR/J mice; old mice, 16–24 months for C57BL/6J mice
and 7–9 months for AKR/J mice. C57BL/6J mice were inoculated s.c. with
2.2 105 cells of B16 melanoma and AKR/J mice were injected by the
same route with 1104 cells of AKR lymphoma. Control—nontreated
tumor-bearing mice; HC—the mice were treated with 500 Ag/mouse of
hydrocortisone at a single dose, injected intratumorally on day 1 after tumor
cell inoculation; ADR—the mice were treated with 25 Ag/mouse of
adriamycin at a single dose, injected intratumorally on day 1 after tumor
cell inoculation. S/T= surviving/total number of mice; %S= percentage of
surviving mice.
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noma as compared to normal spleen (Fig. 3A) shows that
the majority of the cells is tetraploid. This has been reported
for the murine B16 melanoma [34,35] as well as for highly
malignant human melanoma [35,36]. The AKR lymphoma
displays a near diploid cell population. In both tumors, a
decrease in proliferative cell fraction (S +G2M) (significant
in B16 melanoma and at the limit of significance in AKR
lymphoma) concomitant with an increase in apoptotic cell
fraction (sub G1 population) (significant in AKR lympho-
ma, nonsignificant in B16 melanoma) is seen in old as
compared to young mice. When the ratio of proliferative cell
fraction per apoptotic cell fraction of the different experi-
ments is calculated, a sharp decrease in this ratio is seen inTable 2
Assessment of statistical significance of treated versus nontreated tumor-bearing








B16 melanoma Y HC P< 0.05 0
B16 melanoma O HC N.S. 0
AKR lymphoma Y HC 0.05 <P< 0.1 N
AKR lymphoma O HC P< 0.025 P
B16 melanoma Y ADR Pb0.0005 P
B16 melanoma O ADR Pb0.0005 P
AKR lymphoma Y ADR Pb0.0005 P
AKR lymphoma O ADR Pb0.0005 P
Y=young; O = old. Other details as in Table 1.aged as compared to young mice with both tumors, statis-
tically significant in both cases.
Examination of the expression of apoptosis-related genes
in B16 melanoma and AKR lymphoma (Fig. 4) supports the
results at the cellular level. Tumors from aged mice express
a lower level of Bcl-2 protein as compared to those derived
from young animals. According to the average of six
experiments, the difference was statistically significant
(P < 0.025) in both tumors. Contrary to bcl-2, the expres-
sion of the fas gene was higher in lymphoma cells originat-
ing from the old than in those grown in young mice in the
AKR lymphoma. The difference was statistically significant
(P < 0.025). No Fas receptor expression was detected in
B16 melanoma cells, whether derived from young or from
old mice.
Comparison of caspases 8, 3 and 9 activities, analyzed by
Western blot in cells from B16 melanoma and AKR
lymphoma cells derived from mice of different ages (Fig.
5), generally demonstrates a higher activity of the three
enzymes in B16 melanoma and AKR lymphoma cells from
aged as compared to tumors from young mice. This differ-
ence was lower in the case of caspase 3 in the B16
melanoma. The content in procaspase was higher in caspase
8 in B16 melanoma and in caspase 3 in AKR lymphoma.
The quantitative evaluation shows that all three caspases are
more active in tumors derived from old mice than in those
originating from young ones in both tumors. The differences
reached statistical significance in the case of caspases 8 and
9 in the case of AKR lymphoma and in the case of caspase 9
in B16 melanoma. The lack of significance may be due to
two reasons: first, although the differences between young
and old were consistently observed in each experiment,
there were large differences in band intensities between
the different experiments, resulting in high standard devia-
tions; second, in fact, the differences, in most cases, are
underestimated by the quantitative evaluation because high
intensities appear to be ‘‘seen’’ much below linear relation.
A comparison of ladder type DNA degradation, as seen
by agarose gel electrophoresis, between tumors derived













to the v2 test
.05 <P< 0.1 N.S. N.S. N.S.
.05 <PV 0.1 N.S. N.S. N.S.
.S. P < 0.05 0.05 <P < 0.1 N.S.
< 0.025 N.S. N.S. N.S.
b0.00025 Pb0.0005 Pb0.00025 Pb0.00025
< 0.05 Pb0.0005 0.05 <P < 0.1 N.S.
b0.00025 Pb0.0005 Pb0.00025 P< 0.0125
b0.00025 P < 0.0025 Pb0.00025 P< 0.0005
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those derived from young mice in AKR lymphoma (Fig.
5C). Similar results were obtained with the B16 melanoma
(not shown).
3.3. Differential effect of apoptosis-inducing agent therapy
(hydrocortisone and adriamycin) on tumors in young and
old mice
Fig. 6 presents the effect of hydrocortisone treatment on
B16 melanoma and AKR lymphoma growth in young andFig. 10. Induction of cell apoptosis by hydrocortisone (HC) and adriamycin (A
treatment on apoptotic cell fraction. (B) Effect of ADR and HC on caspases 3 and 9
cell death in young and old mice according to DNA degradation. HELA—HeLa c
MT—metastatic tumor; Y—young mice; O—old mice; N.T.—nontreated; HC—hold mice in a representative experiment. The results dem-
onstrate a very marked inhibition of the growth of both
tumors in aged animals. The difference in the average tumor
size between the HC-treated as compared to nontreated aged
tumor-bearing mice was statistically highly significant
(P < 0.005) in both malignancies. In young mice, by con-
trast, AKR lymphoma was not inhibited by hydrocortisone.
Moreover, in the B16 melanoma, a slight tumor enhance-
ment by HC was seen. Hydrocortisone markedly delayed
the mortality of old mice in both B16 melanoma and AKR
lymphoma. Mice mortality in young mice was, by contrast,DR) in B16 melanoma and AKR lymphoma. (A) Effect of in vitro ADR
activities on AKR lymphoma of young mice. (C) Effect of HC on apoptotic
ells; P—procaspase; A—active caspase; M–marker; N.Sp.—normal spleen;
ydrocortisone-treated mice; ADR—adriamycin-treated mice.
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both tumors.
Treatment by adriamycin, shown in a representative
experiment (Fig. 7), contrary to our anticipation, inhibited
the B16 melanoma more markedly in young than in old
mice, in terms of tumor incidence (not shown), tumor size
and mice mortality. In AKR lymphoma, nevertheless, as
with hydrocortisone, ADR had a higher tumor inhibitory
effect on tumors from aged animals than in those from
young ones. This was demonstrated by tumor incidence (not
shown) and size as well as by mice mortality rate, including
the number of long-term survivors.
Figs. 8 and 9 summarize the data of all experiments done
with regard to hydrocortisone and adriamycin treatment,
respectively, in relation to tumor incidence and mice mor-
tality, for B16 melanoma and AKR lymphoma. Table 1
summarizes the data regarding long-term survival (LTS) for
the two treatments for both tumors. Table 2 presents the
statistical evaluation of the efficiency of treatments accord-
ing to different statistical tests.
The effect of hydrocortisone on B16 melanoma
appears to be slightly more efficient in old than in young
mice (Fig. 8), according to the mean day of 50%
incidence and according to the mean survival time (see
inserts). The differences between treated and nontreated
mice were, however, nonsignificant according to most
statistical tests in both young and even less so in old
mice (see Table 2).
As for the AKR lymphoma, old-mice-derived tumors
were more affected by hydrocortisone than young ones
according to the cumulative incidence of tumors (see insert
in Fig. 8). This difference between the effect of HC on the
lymphoma in young and old mice is statistically more
significant in aged mice, both according to the average
day of incidence and according to the Log-rank test (Table
2). Mortality, however, was more rapid in old than in young
mice (same table).
The effect of adriamycin on B16 melanoma in young and
old mice, as summarized in Fig. 9, shows (contrary to our
expectation) that ADR affected more efficiently the tumors
of young mice than those from old animals. This is seen
according to both the Log-rank test and the v2 test for the
comparison of the long-term survivors (Table 2).
The AKR lymphoma was, however, clearly more mark-
edly affected in old than in young animals: see inserts in
Fig. 9 and statistical evaluation of the significance of the
long-term survivors data in Table 2.
Fig. 10 shows that both hydrocortisone and adriamycin
induce apoptosis in vitro, in both B16 melanoma and AKR
lymphoma. The effect of ADR was more pronounced on the
AKR lymphoma than on the B16 melanoma cells (Fig 10A).
Both adriamycin and hydrocortisone treatments increased
activation of caspases 3 and 9 (Fig. 10B).
Fig. 10C shows, according to DNA degradation, that
hydrocortisone induces a higher rate of apoptosis in tumors
of old than in those of young mice, in both AKR lymphomaand B16 melanoma. In the case of AKR lymphoma,
metastatic tumors are presented in Fig. 10, while in Fig. 5
DNA degradation of primary tumors is shown. We have
previously shown that metastatic cells have a much lower
tendency to apoptosis than primary AKR lymphoma cells
[37]. In the case of metastatic cells, DNA degradation
appears partly typical for necrotic cells. However, apoptotic
cells can become necrotic [38].
Both hydrocortisone and adriamycin induce apoptosis in
AKR lymphoma and B16 melanoma. Moreover, hydrocor-
tisone provokes a more marked effect on tumors growing in
old than in those derived from young mice.4. Discussion
The increasing number of elderly cancer patients imposes
a more complex therapeutic approach in this population, in
view of the decreased homeostatic reserve and the increased
prevalence of concomitant diseases so often encountered in
the old. Functional status and comorbidity have to be taken
into account in determining the eligibility of elderly cancer
patients for chemotherapy [39].
Aged cancer patients are often offered suboptimal treat-
ment. In fact, the elderly have been routinely underrepre-
sented or excluded from most cancer studies [40]. Recently,
however, agreement has been reached that age alone should
not be the only consideration in making treatment decisions
[39].
In addition to the abovementioned differences between
young and old cancer patients (which must be taken into
account), it seems that the tumor itself may behave differ-
ently in hosts of different ages. Various authors [1–7] as
well as ourselves [8,9] demonstrated such an age-dependent
differential biological behavior of tumors.
Our previous studies [8] were related to B16 melanoma.
Here we showed that the AKR lymphoma as well grows at a
markedly slower rate in old as compared to young mice.
This was seen according to cumulative incidence and size of
tumors. Mice mortality was, however, in most experiments,
accelerated in old as compared to young mice. This finding
is difficult to explain and merits further research. It is
possible that the high apoptotic cell level and possibly
necrotic cells derived from the apoptotic bodies [38] of
the tumor induce some systemic damage provoking an
earlier mortality. Indeed, tumor suppression was recently
found to be accompanied by accelerated aging in p53-
overexpressing mice [41] and antitumoral intervention has
been suggested to eventually affect aging [42], possibly via
apoptosis.
We suggest that the age-related differential tumor biology
should also be taken into account in the design of treatment
modalities for the aged. Understanding the mechanism(s)
responsible for the age-related biological behavior of tumors
may permit a logical design of age-adjusted anti-tumoral
therapy.
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and in AKR lymphoma that increased apoptotic cell death is
at least one of the mechanisms responsible for the age-
related reduced malignancy of tumors. We demonstrated an
increase in apoptotic cell death in tumors derived from old
as compared to young mice, according to cell morphology,
DNA fragmentation, modification in apoptosis-related gene
expression (bcl-2 and fas) and increased caspase 8, 3 and 9
activities.
Various groups [43,44] and ourselves [45] have shown
increased apoptosis with increasing age in normal tissues.
We suggest that apoptosis-inducers may be present in
normal aged organs and these might affect tumor cells
situated in this environment, thereby reducing tumor
growth. Indeed, healthy cells can be induced to die by
apoptosis if exposed to the medium conditioned by senes-
cent cells of the same or even different species [46].
We postulated that it may be possible to design age-
adjusted treatment modalities based on the mechanism(s)
responsible for the reduced tumor progression rate in the
aged. One of these mechanisms is a decline in the
proliferative capacity of tumor cells with age [11]. How-
ever, decreased proliferative ability implies decreased sen-
sitivity to drugs. Classical antiproliferative chemotherapy is
therefore expected to be less efficient against cancer in the
old. This in fact constitutes an additional hindrance in
cancer treatment of the aged. For instance, breast tumors in
elderly patients display an indolent behavior, implying a
lower proliferative rate and therefore a lower susceptibility
to cytotoxic agents [40]. Inducing apoptosis, instead of
acting on cell proliferative ability, might therefore have an
additional advantage of avoiding this age-related drug-
resistance.
Based on our results, pointing to an increased apoptotic
cell death as being one of the mechanisms responsible for
the reduced tumor aggressiveness in the old, we attempted
to discover whether treatment with apoptosis-inducing drugs
might result in differential treatment efficacy in old and
young tumor-bearing mice. We compared the treatment
efficacy of two apoptosis-inducing agents, hydrocortisone
and adriamycin, on tumors growing in mice of different
ages. Hydrocortisone, which acts as a potent specific induc-
er of apoptosis, was more efficient against tumors growing
in old than in those growing in young mice, in both B16
melanoma and more so in the AKR lymphoma, according to
incidence and size of tumors. While this same tendency was
observed with ADR treatment of AKR lymphoma, opposite
results were obtained in B16 melanoma treatment: ADR
therapy was more efficient in young than in old mice. This
was evident according to incidence and size of tumors as
well as according to the data regarding long-term survivors.
We have also demonstrated that the differential effects of
both hydrocortisone and adriamycin can, at least partly, be
due to induction of apoptotic cell death.
It is now well established that many chemotherapeutic
drugs, including adriamycin, exert their effect, at leastpartially, by apoptosis [47]. The cytotoxic effect of chemo-
therapeutic agents depends on Fas and Fas ligand [48]. Loss
of Fas expression during chemotherapy constitutes one of
the mechanisms of cancer drug resistance.
Due to their ‘‘lympholytic effect’’, adrenal corticosteroids
have been used to treat lymphomas since the late 1940s
[49]. Lymphoid and leukemic cells are generally prone to
apoptosis and, moreover, uniquely sensitive to the lytic
action of glucocorticoid hormones [50].
It is believed that the caspase cascade activated by GC
occurs through mitochondria and not through membrane
death receptors such as Fas [51]. In AKR lymphoma and
B16 melanoma, both the extrinsic (involving caspase-8) and
the intrinsic (mitochondria-mediated, involving caspase-9)
pathways of caspase-activating cascades [52] were more
active in old than in young mice (Fig. 3A).
An age-related increase of glucocorticoid levels has been
reported in the literature [53]. Elevated corticosteroids, as
well as elevated tumor necrosis factor [54] with aging,
might be the reason for the increased apoptosis that we
have shown to occur in normal tissues derived from aged
mice [45] as well as in tumors growing in aged mice (shown
here). It is therefore possible that tumors in old organisms
are more prone to apoptosis due to the presence of apopto-
sis-inducers in their microenvironment. Apoptosis-inducing
therapy may prove to be far less toxic than antimitotics [55],
which in itself is of importance for the aged cancer patient.
To explain the different action exerted by ADR on B16
melanoma, the following can be said: GC-signaling to
apoptosis is essentially different from that of cytostatic
drugs or ionizing radiation. Glucocorticoids can kill their
sensitive target cells only by inducing programmed cell
death whereas the contribution of apoptosis to the total
level of tumor cell kill by cytostatic drugs such as adria-
mycin and radiation is a matter of debate [56]. Thus,
mechanisms other than apoptosis-induction (such as anti-
proliferative effect) may be responsible for the higher effect
of ADR on B16 melanoma of young mice, which may not
be efficient against tumors of old mice. In this sense,
adriamycin (and cytotoxic agents in general) is not a purely
apoptosis-inducing agent. In addition, the B16 melanoma
appears to be less prone to apoptosis than the AKR
lymphoma. Indeed, it is not expected that all apoptosis-
inducing treatments will be more effective in old mice
against each tumor. However, in view of the rapidly in-
creasing aged population and the paucity of efficient anti-
tumoral treatments in the aged, it may be of importance if
such a mechanism of treatment will be effective in some
tumors.
Since elderly cancer patients are usually considered
unsuited for the often aggressive therapeutic modalities
now applied to cancer patients, it may be of high importance
to find that milder treatments could be appropriate for
patients of advanced age. Our finding that certain apopto-
sis-inducing agents, in certain tumors, might be even more
efficient against tumors in old organisms is particularly
O. Itzhaki et al. / Biochimica et Biophysica Acta 1688 (2004) 145–159158encouraging. This in view of the accepted dogma (and of the
massive data published in this field) that cancer treatment is
less efficient and more dangerous for the elderly patient.
The differential malignant behavior of tumors in old as
compared to young patients might impose a new concept in
the treatment of elderly cancer patients. While aging is
considered to preclude current (mainly antiproliferative)
antitumoral treatments, therapeutic modalities based on
other mechanisms (those shown to be responsible for the
reduced tumor progression rate in the old) might be as
efficient or even more efficient in aged than in young
organisms.
The understanding of the mechanisms underlying the
reduced aggressiveness of tumors in the aged might be of
high importance since it may shed some light on yet
unknown physiological means able to inhibit or confine
tumor growth. Moreover, information about these presumed
natural antitumoral means might suggest new therapeutic
targets not only for old but also for young people.Acknowledgements
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